Just days after Eli Lilly announced plans to cut the price of its insulin products in the ... After Lilly broke ranks, both Novo Nordisk and Sanofi were criticised by long-time pharma critic ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time.

Dublin, March 06, 2025 (GLOBE NEWSWIRE) -- The "Insulin Pens Market Size by Segments, Share, Regulatory, Reimbursement and Forecast to 2036" report has been added to ResearchAndMarkets.com's offering.

With Ozempic now the world’s top-selling diabetes drug and Wegovy ... its first-mover advantage over rival Eli Lilly (NYSE:LLY). Yet Novo Nordisk’s growth prospects are far from guaranteed ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Now Novo Nordisk and Indianapolis-based rival Eli Lilly and Co. are seeking to capture the large market of consumers who purchased compounded weight-loss drugs to get lower prices. David Kim ...

According to TD Cowen, Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO) which offer obesity/ diabetes drugs, tirzepatide and semaglutide will be competing neck and neck in the GLP-1 market in 2030 with ...

Shares of Novo Nordisk (NVO ... for CagriSema across diabetes and obesity. With REDEFINE-2 headlines showing limited differentiation for Novo’s CagriSema vs. Eli Lilly’s tirzepatide in ...

and diabetes medications. More on Eli Lilly, Novo Nordisk A/S, etc. Eli Lilly and Company (LLY) TD Cowen 45th Annual Health Care Conference (Transcript) Novo Nordisk A/S 2024 Q4 - Results ...